Vertex Pharmaceuticals Incorporated(Nasdaq: VRTX) today announced new interim data from the ALYFTREK®(vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results